However, its application to solid tumors remains constrained by antigen heterogeneity and on-target, off-tumor toxicities. One critical emerging approach to combat this challenge is logic-gated ...

Tumor heterogeneity and tumor mutational burden (TMB) are novel biomarkers associated with the response to immunotherapy in non-small cell lung cancer (NSCLC), but studies report conflicting results.

This heterogeneity complicates the consistent delivery of therapeutic agents ... CAR-T cell therapy involves modifying a patient’s T cells to express chimeric antigen receptors that recognize specific ...

Moreover, the stromal heterogeneity as well as genetic and epigenetic changes that impact PDAC ... granulocyte–macrophage colony-stimulating factor (GM-CSF), stimulate T cells, NK cells or tumor ...

CAR-T cell therapy is a breakthrough in cancer immunotherapy. The treatment is available in India at a fraction of the cost abroad. Among the many emerging treatments for cancer, there's one called ...

This personalized chimeric antigen receptor (CAR) T cell therapy will attack a wider range of cancer cells, and block cancer's defense mechanisms to empower the immune system to better fight cancer.

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Negative Breast Cancer Market Insight, Epidemiology and Market Forecast - 2035" report delivers comprehensive insights into triple-negative breast cancer, i ...